Literature DB >> 9551948

CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

P J Blair1, J L Riley, B L Levine, K P Lee, N Craighead, T Francomano, S J Perfetto, G S Gray, B M Carreno, C H June.   

Abstract

We have assessed the functional effects of a panel of CTLA-4 mAbs on resting human CD4+ T cells. Our results demonstrate that some CTLA-4 mAbs can inhibit proliferative responses of resting CD4+ cells and cell cycle transition from G0 to G1. The inhibitory effects of CTLA-4 were evident within 4 h, at a time when cell surface CTLA-4 expression remained undetectable. Other CTLA-4 mAbs had no detectable inhibitory effects, indicating that binding of Ab to CTLA-4 alone is not sufficient to mediate down-regulation of T cell responses. Interestingly, while IL-2 production was shut off, inhibitory anti-CTLA-4 mAbs permitted induction and expression of the cell survival gene bcl-X(L). Consistent with this observation, cells remained viable and apoptosis was not detected after CTLA-4 ligation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

Review 1.  PD-1 signaling in primary T cells.

Authors:  James L Riley
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

3.  Cdc18 transcription and proteolysis couple S phase to passage through mitosis.

Authors:  B Baum; H Nishitani; S Yanow; P Nurse
Journal:  EMBO J       Date:  1998-10-01       Impact factor: 11.598

4.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking.

Authors:  P Scheipers; H Reiser
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

5.  Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

Authors:  R Tohn; H Blumenfeld; S M M Haeryfar; N Veerapen; G S Besra; S A Porcelli; T L Delovitch
Journal:  Clin Exp Immunol       Date:  2011-03-01       Impact factor: 4.330

Review 6.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

7.  Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Authors:  Dalil Hannani; Marie Vétizou; David Enot; Sylvie Rusakiewicz; Nathalie Chaput; David Klatzmann; Melanie Desbois; Nicolas Jacquelot; Nadège Vimond; Salem Chouaib; Christine Mateus; James P Allison; Antoni Ribas; Jedd D Wolchok; Jianda Yuan; Philip Wong; Michael Postow; Andrzej Mackiewicz; Jacek Mackiewicz; Dirk Schadendorff; Dirk Jaeger; Inka Zörnig; Jessica Hassel; Alan J Korman; Keith Bahjat; Michele Maio; Luana Calabro; Michele Wl Teng; Mark J Smyth; Alexander Eggermont; Caroline Robert; Guido Kroemer; Laurence Zitvogel
Journal:  Cell Res       Date:  2015-01-13       Impact factor: 25.617

8.  Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.

Authors:  K Vandenborre; S W Van Gool; A Kasran; J L Ceuppens; M A Boogaerts; P Vandenberghe
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

Review 9.  Mechanisms and assessment of lectin-mediated mitogenesis.

Authors:  D C Kilpatrick
Journal:  Mol Biotechnol       Date:  1999-02       Impact factor: 2.695

Review 10.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.